Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment

Author(s): Qingyong Ma, Zheng Wang, Min Zhang, Hengtong Hu, Junhui Li, Dong Zhang, Kun Guo, Huanchen Sha

Journal Name: Current Pharmaceutical Design

Volume 16 , Issue 4 , 2010

Become EABM
Become Reviewer
Call for Editor


The action of L-arginine is mainly dependent on its end-product, nitric oxide (NO). The L-arginine/NO pathway has been confirmed to play an important role in tumor development. Recent findings indicate that NO derived from L-arginine could influence angiogenesis factors, vascular permeability, perivascular-cell recruitment and vessel remodeling and maturation. Additionally, the Larginine/ NO pathway could activate a broad array of genes that are functionally involved in proliferation, metastasis and apoptosis. Interestingly, this pathway plays roles in both tumorigensis and tumor killing. The role of the L-arginine/NO pathway in tumor therapy has been well-studied. Members of this pathway have been reported to be promising therapeutic molecules in tumor therapy. This review article summarizes research data on the roles of the L-arginine/NO pathway in cancer biology and cancer therapy.

Keywords: L-arginine, nitric oxide, nitric oxide synthase, tumor, cell apoptosis, cell proliferation, metastasis, cancer therapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [392 - 410]
Pages: 19
DOI: 10.2174/138161210790232121
Price: $65

Article Metrics

PDF: 30